The AYA Cancer Gap: Why Adolescents and Young Adults Face Adversity Again

The AYA Cancer Gap: Why Adolescents and Young Adults Face Adversity Again

Adolescents and young adults (AYAs) with cancer are facing a troubling resurgence of disparities. Despite past progress, rising cancer incidence, mental health challenges, and healthcare policy threats are widening the AYA cancer gap again.

Introduction: A Gap We Narrowed, and Now Fear Returning — Understanding the AYA Cancer Survival Gap

When I stood before colleagues at Binaytara's 2026 Summit on Cancer Health Disparities, I chose the title "Mind the AYA Gap Again: Adversity Yet Again" deliberately. The word again is doing a lot of work in that sentence.

In the 1990s, as chair of the Children's Cancer Group, I was proud of the progress we had made in childhood cancer survival — progress built painstakingly on decades of clinical trial evidence. But when I turned my attention to adolescents and young adults, I was struck by something deeply uncomfortable: we had not achieved the same gains. Children were surviving at dramatically higher rates. Older adults were improving. But the population we now call AYAs — those aged 15 to 39 — had been left behind.

We called it "minding the gap," borrowing from the London Underground. We coined the term AYA in the context of oncology. And for a time, we made real progress. But today, as I look at the data again, I find myself in familiar and troubling territory. The gap has not closed in many other ways — and in the U.S., new adversities are threatening to widen it

The Original Disparity: How Survival Trends Changed Over Time

The Original Disparity in AYA Cancer Outcomes

The survival curves tell the story clearly. In 1980, five-year survival rates for cancer patients followed a broad arc across age groups — with AYAs actually faring slightly better than children in some comparisons. But by 1995, that picture had changed dramatically. Children under 15 had made enormous gains in survival. Middle-aged and older adults had improved as well. AYAs, aged 15 to 39, had not — and in some analyses, their survival had actually declined relative to these other groups.

This was the AYA gap. And it was not a small one.

Progress Through Clinical Trials and Biology Insights

When we looked at the subsequent period — outcomes for patients diagnosed after 2016 — we finally began to see meaningful progress in the AYA group. This was a significant and deeply personal milestone for me. The improvement was real, and it was largely attributable to clinical trials: to the discipline we built, the fellowship programs we created, the international networks we established, and — critically — to the discovery that AYA cancers are biologically distinct from the "same" cancers in younger or older patients.

A leukemia diagnosed in a 25-year-old is not the same disease as a leukemia diagnosed in a 7-year-old, even when pathologists give them the same name. AYA ALL, for example, is often Ph-like — a biologically distinct category that requires different therapeutic approaches. Learning this was essential. Applying it, through dedicated clinical trials and new agents, is what drove the improvement we finally observed.

The New Setbacks: Three Emerging Threats to AYA Cancer Progress

Progress is not permanent. As I reviewed the current data in preparation for this talk, I identified three serious and active setbacks that place AYA cancer outcomes at risk — and that, taken together, represent the "Adversity Yet Again" in my title.

Rising Cancer Incidence in Young Adults

The number of new cancer cases among AYAs is increasing — and it is increasing faster than in any other age group. In the year 2000, approximately 67,000 new cancer cases were diagnosed annually in 15-to-39-year-olds in the United States. By 2022, that number had risen 21 percent to more than 81,000. By comparison, cancer cases in children under 15 rose only about 9 percent over the same period, from 8,900 to 9,700. In AYAs, we have identified 35 types of invasive cancer with statistically-significant age-adjusted incidence increases.

We do not yet fully understand why this is happening. Reversing it is one of the defining challenges of AYA oncology going forward.

Mental Health Crisis and Suicide Risk in AYA Patients

This is the finding that I find most disturbing, and I want to be direct about it. The suicide rate among AYAs diagnosed with cancer in the U.S. has risen steadily since 2001 and continues to climb. Suicide is now the fourth leading cause of death among newly diagnosed AYA cancer patients in the United States — behind only cancer recurrence, second malignancies, and treatment-related complications. The vast majority of these deaths involve firearms.

This is not a distant statistic. It reflects the profound psychosocial burden that a cancer diagnosis places on a young person during what should be the most formative years of their life — years when identity, relationships, and life milestones are being formed. It also reflects the broader mental health crisis affecting young Americans, in which social isolation is playing an increasingly significant role.

Financial Toxicity and the Threat to the Affordable Care Act

The Affordable Care Act transformed insurance coverage for young adults. Before its passage, approximately one-third of Americans aged 19 to 25 were uninsured. Within four years of the ACA's implementation, that rate dropped by half — a dramatic and measurable improvement. Among AYAs of the age that the ACA allowed them to stay on their parent’s insurance, their cancer survival rate within 5 years after the ACA was implemented improved twice that in younger and older cancer patients. Dr. Bleyer and colleagues in California, Texas and Tennessee reported this progress a year ago January.

My colleague Anao and I have since been working on the relationship between Medicaid expansion and cancer mortality in AYAs of age 19 to 39. The data show that in the forty states that adopted Medicaid expansion, the AYA cancer death rate declined meaningfully after 2010 — and significantly more than in the ten non-expansion states. For patients under 18, who would not have been directly affected by the ACA's dependent coverage provision, the curves are nearly identical between expansion and non-expansion states —what you would be expected if the ACA was the reason.

This is not proof of causation, but it is a powerful and consistent signal. And it is a signal we are about to test in reverse, as Medicaid funding faces cuts that could undo much of what was accomplished. We want to be clear: the policy stakes here for AYA cancer patients and their quality and quantity of life are very real.

Clinical Implications: What Oncology Providers Need to Do Now

Why AYA Cancer Biology Requires Different Treatment

The AYA population is better served by combined pediatric and adult oncology systems. Pediatric institutions and children’s hospitals are not designed for a 18- to 39year-olds navigating a cancer diagnosis alongside a career, a mortgage, and a young family. Adult institutions are optimized for older patients and their types of cancer that are distinctly different. They also often lack the time, staff, and programming to meet AYA-specific needs, and especially their psychosocial, sexual, family and financial challenges.

What can individual providers do?

The Role of Clinical Trials in Improving Outcomes

Recognize that most AYA cancers are biologically distinct. Do not assume that a cancer in a 28-year-old is the same disease as its histologic equivalent in a 65-year-old. Enroll AYA patients in clinical trials whenever possible — this is how we made progress before, and it is how we will make progress again.

Addressing Psychosocial and Mental Health Needs

Screen for psychosocial risk. The suicide data demand that we take mental health assessment seriously and consistently in this population. Firearms access is a specific and modifiable risk factor that should be part of these conversations.

Advocate for AYA-specific programming at your institution. This does not require a dedicated hospital wing. It requires champions — clinicians, nurses, social workers, and administrators who are willing to make AYA care a priority and build sustainable infrastructure around it.

What AYA Patients and Families Should Know

If you are an AYA facing a cancer diagnosis, or if you are caring for one, you should know: your experience is different from that of an older cancer patient, and it deserves to be treated that way. The challenges are real — financially, emotionally, and medically. But so is the community of people who are working to help you.

Ask your oncologist whether your cancer has been evaluated for AYA-specific biology. Ask about clinical trial eligibility. Seek out AYA-focused resources and peer support programs — they exist and they matter. Ask if you should be referred to a comprehensive cancer center with specific AYA resources. And if you or someone you love is struggling emotionally, please talk to your care team.

Key Takeaways

• AYAs (ages 15–39) represent the fastest-growing cancer incidence group in the United States, with new diagnoses up 21% since 2000.
• Survival gaps between AYAs and other age groups have narrowed — but progress is threatened by rising incidence, worsening mental health outcomes, and potential rollbacks of the Affordable Care Act.
• Suicide is now the fourth leading cause of death among newly diagnosed AYA cancer patients in the U.S., with firearms the predominant method.
• The Affordable Care Act and Medicaid expansion has been associated with measurable increases in cancer survival and reductions in cancer mortality among AYAs — progress now threatened nationally.
• AYA cancers are biologically distinct from the same diagnoses in younger or older patients, and clinical trials remain the most powerful tool we have to improve outcomes. AYAs should enroll on the trials whenever possible.

About the Author

Dr. Archie Bleyer is former chair of the Children's Cancer Group and founder of adolescent and young adult (AYA) oncology, He was among the first researchers to identify and name the survival disparity between AYA cancer patients and both younger and older populations — a gap he has spent three decades working to close. He is the editor of the landmark textbook Cancer in Adolescents and Young Adults, has been affiliated with multiple NCI-sponsored research programs, the University of Washington’s Global Health Burden program, and currently is Clinical Research Professor at the Knight Cancer Institute and Oregon Health and Science University..

Frequently Asked Questions About AYA Cancer

What is AYA cancer?

AYA cancer refers to cancers diagnosed in adolescents and young adults between the ages of 15 and 39.

Why do AYA cancer patients face worse outcomes?

AYA patients often experience delayed diagnosis, unique cancer biology, lower clinical trial participation, and gaps in care between pediatric and adult oncology systems.

Is cancer increasing among young adults?

Yes. Cancer incidence among AYAs has risen by over 20% since 2000, making it the fastest-growing age group for cancer diagnoses.

Why is mental health a major concern in AYA cancer?

Cancer disrupts key life stages, increasing stress, isolation, and depression. Suicide is now the fourth leading cause of death among AYA cancer patients.

How has the Affordable Care Act impacted AYA cancer survival?

The ACA improved insurance access, which has been linked to better survival rates and reduced mortality in young adult cancer patients.

References

1. Bleyer A. “Overview: Cancer in adolescents and young adults: Epidemiology, diagnosis, treatment, survival, and importance of clinical trials.” Med Pediatr Oncol.
2. Bleyer A, et al. “Role of clinical trials in survival progress of American adolescents and young adults with cancer – and lack thereof.” Pediat Blood Ca.
3. Roth M, … Bleyer A. “Improved survival and decreased cancer deaths in young adults with cancer after passage of the Affordable Care Act Dependent Coverage Expansion.” Cancer.
4. “Impact of lagtime, health insurance type and income status at diagnosis on the long-term survival of adolescent and young adult cancer patients.” J Adol Young Adult Oncol
5. Bleyer A, Barr R, et al. Cancer in Adolescents and Young Adults, 2nd edition. Springer.
6. Zhang A, Bleyer A, Zhang A et al. Bleyer A, Zhang A, Kahn JM, DuVall AS, Estrada J, Zebrack BJ. Decreased cancer deaths in young adults in Medicaid states after passage of the Affordable Care Act and its Dependent Coverage Expansion. (Manuscript under review.)
7. Binaytara. Session 14B: Youth & Early-Onset Cancer in Underrepresented Populations. 2026 Summit on Cancer Health Disparities.